We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Radical Prostatectomy and Perioperative Fluid Therapy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00771966
First Posted: October 15, 2008
Last Update Posted: October 22, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Morten Bundgaard-Nielsen, Rigshospitalet, Denmark
  Purpose

The optimal amount of fluid a patient need under surgery is not clear. Both to much and to little fluid can damage the organ functions.

A strategy called "Goal directed therapy", where the fluid amount a patient need is guided by the stroke volume, has shown to minimize post-operative nausea and vomiting.

The investigators intend to investigate if patients treated after these standards, has a better outcome then patients treated after normal regimes, regarding post-operative orthostatic-intolerance.


Condition Intervention Phase
Prostate Cancer Procedure: Standard therapy Procedure: Maximization of cardiac stroke volume with fluid infusion Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Radical Prostatectomy and Perioperative Fluid Therapy

Resource links provided by NLM:


Further study details as provided by Morten Bundgaard-Nielsen, Rigshospitalet, Denmark:

Primary Outcome Measures:
  • To investigate orthostatic cardiovascular response and orthostatic intolerance in patients after removal of the prostate [ Time Frame: 6 hours ]

Secondary Outcome Measures:
  • Investigate intraoperative haemodynamics [ Time Frame: Intraoperative ]

Enrollment: 44
Study Start Date: October 2008
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Standard treatment Procedure: Standard therapy
Standard therapy
Active Comparator: SV maximization Procedure: Maximization of cardiac stroke volume with fluid infusion
Maximization of cardiac stroke volume with fluid infusion

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with cancer in there prostate

Exclusion Criteria:

  • Patients who don't understand the information
  • ASA > III
  • Patients that are under treatment with the drug triazolam
  • Patients with af known renal decease
  • Patients with a psychiatric decease
  • Alcohol abuse
  • Severe haemorrhagic decease
  • Cancer in the mouth,pharynx, larynx or oesophagus
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00771966


Locations
Denmark
Dept of anesthesiology, Rigshospitalet
Copenhagen, Denmark
Sponsors and Collaborators
Rigshospitalet, Denmark
  More Information

Responsible Party: Morten Bundgaard-Nielsen, MD, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT00771966     History of Changes
Other Study ID Numbers: RCT_PROST_ORTO
First Submitted: October 14, 2008
First Posted: October 15, 2008
Last Update Posted: October 22, 2012
Last Verified: October 2012

Keywords provided by Morten Bundgaard-Nielsen, Rigshospitalet, Denmark:
patients with cancer in the prostate